시장보고서

상품코드

1842244

미국의 동물용 안과 의료 시장 규모, 점유율, 동향 분석 : 동물별, 제품별, 적응증별, 유통 채널별, 부문별 예측(2025-2033년)

U.S. Veterinary Eye Care Market Size, Share & Trends Analysis Report By Animal (Canine, Feline, Equine, Bovine), By Product (Devices & Instruments, Medications), By Indication, By Distribution Channel, And Segment Forecasts, 2025 - 2033

발행일: 2025년 09월 | 리서치사:

Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

미국의 동물용 안과 의료 시장 개요

미국의 동물용 안과 의료 시장 규모는 2024년에 16억 6,000만 달러로 평가되었으며, 2033년에는 27억 1,000만 달러에 달할 것으로 예측되며, 2025년부터 2033년까지 CAGR은 5.6%로 성장할 전망입니다.

이 시장은 동물용 안과 의료 수단의 확대, 항생제의 합리적 사용 옹호 증가, 수의학 전문가의 인식 확산에 대한 참여 증가, 동물용 안과 의료의 기술 발전 등의 요인에 의해 발전하고 있습니다.

미국의 동물용 안과 의료 분야는 수술 기술, 유전자 연구, 진단 기술의 발전에 힘입어 괄목할 만한 성장을 거듭하고 있습니다. 이러한 개발로 동물 안과 치료의 범위가 넓어지고 있으며, 과거에는 치료가 불가능하다고 여겨졌던 질병에도 새로운 희망을 가져다주고 있습니다.

그 대표적인 예가 2025년 1월 UC Davis에서 시행한 개 망막열공 치료를 위한 망막 재접합 수술(retinopexy)의 사용입니다. 이 수술은 안구 내 천연 젤을 실리콘 오일로 대체하여 망막의 위치를 바꾸어 환자의 시력을 효과적으로 회복시키는 수술입니다. 이러한 전문적인 수술은 수술 장비와 훈련의 향상으로 더욱 친숙해지고 있습니다.

유전자 연구 또한 동물용 안과 의료에서 매우 중요한 역할을 하고 있습니다. dvm360이 2025년 3월에 발표한 논문과 같은 연구는 개의 진행성 망막위축증(PRA)과 같은 증상을 유발하는 특정 유전자 변이를 확인했습니다. 예를 들어, GTPBP2 유전자의 3염기쌍 결실은 PRA와 관련이 있으며, 유전자 검사와 정보에 입각한 번식 결정의 근거가 되고 있습니다. 이 접근법은 이러한 병의 유전적 전파를 방지하여 미래 세대의 유병률을 감소시키는 것을 목표로 하고 있습니다.

고양이 녹내장 관리에서 라타노프로스트의 사용은 치료 옵션이라는 측면에서 동물 안과 의료의 복잡성을 강조하고 있습니다. 라타노프로스트는 고양이의 안압 강하에 효과적이지만, 그 한계는 고양이의 생리에 맞는 보다 효과적인 치료법의 지속적인 연구 개발의 필요성을 강조하고 있습니다.

또한, 개 눈꺼풀 종양 치료에 레이저 기술이 채택된 것은 비침습적 수술 기술의 큰 진전입니다. dvm360이 2025년 3월에 발표한 기사에 따르면, 레이저 치료는 기존 방식에 비해 정확도가 높고 회복 시간도 단축되어 반려동물과 보호자 모두에게 전반적인 치료 경험을 향상시킬 수 있다고 합니다.

이러한 기술 혁신이 쌓여 역동적이고 빠르게 진화하는 동물용 안과 의료에 기여하고 있습니다. 이 분야가 계속 발전함에 따라, 전문적이고 배려심 있는 수의학을 추구하는 광범위한 추세를 반영하여 다양한 안질환을 앓고 있는 동물들의 치료 성과가 향상될 것으로 기대됩니다.

부문 대시보드
미국의 동물용 안과 의료 시장 : 변동 분석, 제품별
미국의 동물용 안과 의료 시장 규모와 동향 분석 : 제품별(2021-2033년)
디바이스와 기기
치료 기기
의약품
- 의약품 매출 추정과 예측, 2021-2033년
- 항생제
- NSAID
- 코르티코스테로이드
- 윤활제/인공눈물
- 진통제
- 기타 약

제6장 미국의 동물용 안과 의료 시장 : 적응증별 추정·동향 분석

부문 대시보드
미국의 동물용 안과 의료 시장 : 변동 분석, 적응증별
미국의 동물용 안과 의료 시장 규모와 동향 분석 : 적응증별(2021-2033년)
- 안검 이상
- 백내장
- 녹내장
- 포도막염
- 결막염
- 각막 합병증
- 기타 적응증

제7장 미국의 동물용 안과 의료 시장 : 유통 채널별 추정·동향 분석

부문 대시보드
미국의 동물용 안과 의료 시장 : 변동 분석, 유통 채널별
미국의 동물용 안과 의료 시장 규모와 동향 분석 : 유통 채널별(2021-2033년)
- 동물 병원·클리닉
- 전문점
- E-Commerce
- 기타 유통 채널

제8장 경쟁 구도

시장 진입 기업 분류
기업의 시장 포지션 분석/히트맵 분석
기업 개요
- Merck & Co., Inc.
- An-Vision GmbH
- Jorgensen Laboratories
- LKC Technologies Inc.
- Accutome Inc.
- Dechra
- Bausch &Lomb Incorporated
- Zoetis Services LLC.
- Ceva Sante Animale
- Sandoz
- Boehringer Ingelheim
- I-Med Animal Health
- Iridex Corporation
- Baxter(Welch Allyn)
- OptoMed
- Reichert, Inc.
- Occuity
- Strategy Mapping
- Mergers &Acquisitions
- Partnerships & Collaborations
- Product launch
- Others
기타 주요 기업 리스트

KSM 25.11.13

U.S. Veterinary Eye Care Market Summary

The U.S. veterinary eye care market size was estimated at USD 1.66 billion in 2024 and is projected to reach USD 2.71 billion by 2033, growing at a CAGR of 5.6% from 2025 to 2033. The market is advancing owing to factors such as expanding veterinary eye care avenues, increasing advocacy for rationale use of antibiotics, growing involvement of veterinary professionals in spreading awareness, and technological advancements in veterinary eye care.

The veterinary eye care sector in the U.S. is experiencing significant growth, driven by advancements in surgical techniques, genetic research, and diagnostic technologies. These developments are expanding the scope of eye care for animals, offering new hope for conditions that were once considered untreatable.

A notable example is the use of retinal reattachment surgery, or retinopexy, conducted in January 2025, by UC Davis, to address retinal tears in dogs. This procedure involves replacing the natural gel in the eye with silicone oil to reposition the retina, effectively restoring vision in affected animals. Such specialized surgeries are becoming more accessible, thanks to improvements in surgical equipment and training.

Genetic research is also playing a pivotal role in veterinary eye care. Studies such as the March 2025 article published by dvm360 have identified specific genetic mutations responsible for conditions such as progressive retinal atrophy (PRA) in dogs. For instance, a 3-base pair deletion in the GTPBP2 gene has been linked to PRA, providing a basis for genetic testing and informed breeding decisions. This approach aims to prevent the hereditary transmission of such conditions, thereby reducing their prevalence in future generations.

In terms of treatment options, the use of latanoprost in managing glaucoma in cats highlights the complexities of veterinary ophthalmology. While latanoprost has shown efficacy in lowering intraocular pressure in cats, its limitations underscore the need for ongoing research and development of more effective therapies tailored to feline physiology.

Furthermore, the adoption of laser technology for treating canine eyelid tumors represents a significant advancement in non-invasive surgical techniques. As per March 2025 article published by dvm360, laser treatments offer precision and reduced recovery times compared to traditional methods, enhancing the overall treatment experience for both pets and their owners.

Collectively, these innovations are contributing to a dynamic and rapidly evolving veterinary ophthalmology landscape. As the field continues to progress, it holds the promise of improved outcomes for animals suffering from a range of ocular conditions, reflecting a broader trend toward specialized and compassionate veterinary care.

U.S. Veterinary Eye Care Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. veterinary eye care market report based on animal, product, indication, and distribution channel:

Animal Outlook (Revenue, USD Million, 2021 - 2033)
Canine
Feline
Equine
Bovine
Others
Product Outlook (Revenue, USD Million, 2021 - 2033)
Devices & Instruments
- Diagnostic Devices
- Tonometers
- Ophthalmic Test Kits
- Electroretinogram (ERG)
- Fundus Camera
- Ophthalmoscopes
- Pachymeter
- Other Diagnostic Devices
- Treatment Devices
- Lenses
- Bandage Lenses
- Intraocular Lenses
- Laser Devices
- Other Treatment Devices
Medications
- Antibiotics
- NSAIDs
- Corticosteroids
- Lubricants / Artificial Tears
- Analgesics / Pain Relievers
- Other Medications
Indication Outlook (Revenue, USD Million, 2021 - 2033)
Eyelid Abnormalities
Cataract
Glaucoma
Retinal Complications
Uveitis
Conjunctivitis
Corneal Complications
Other Indications
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Veterinary Hospitals & Clinics
Specialty Stores
E-Commerce
Other Distribution Channels

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR's Internal Database
- 1.3.3. Secondary Sources
- 1.3.4. Primary Research
1.4. Information/Data Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
- 1.7.1. Commodity flow analysis
- 1.7.2. Country Market: CAGR Calculation
1.8. List of Secondary Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. Veterinary Eye Care Market Variable Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market
- 3.1.2. Ancillary Market
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Expanding Veterinary Eye Care Avenues
  - 3.2.1.2. Increasing Advocacy for Rationale Use of Antibiotics
  - 3.2.1.3. Growing Involvement of Veterinary Professionals in Spreading Awareness
  - 3.2.1.4. Technological Advancements in Veterinary Eye Care
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. High Cost Of Veterinary Ophthalmic Procedures
  - 3.2.2.2. Limitations of Medications in Ophthalmology Care
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.2.5. Industry Analysis
  - 3.2.5.1. Porter's Five Forces Analysis
  - 3.2.5.2. PESTLE by SWOT Analysis
- 3.2.6. Pricing Analysis
- 3.2.7. Estimated Animal Population by key species, 2021 - 2024

Chapter 4. U.S. Veterinary Eye Care Market: Animal Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. U.S. Veterinary Eye Care Market: Animal Movement Analysis
4.3. U.S. Veterinary Eye Care Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
4.4. Canine
- 4.4.1. Canine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Feline
- 4.5.1. Feline Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Equine
- 4.6.1. Equine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Bovine
- 4.7.1. Bovine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Other Animals
- 4.8.1. Other Animals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Veterinary Eye Care Market: Product Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. U.S. Veterinary Eye Care Market: Product Movement Analysis
5.3. U.S. Veterinary Eye Care Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
5.4. Devices & Instruments
- 5.4.1. Devices & Instruments Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.4.1.1. Diagnostic Devices
    - 5.4.1.1.1. Diagnostic Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.4.1.2. Tonometers
    - 5.4.1.2.1. Tonometers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.4.1.3. Ophthalmic Test Kits
    - 5.4.1.3.1. Ophthalmic Test Kits Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.4.1.4. Electroretinogram (ERG)
    - 5.4.1.4.1. Electroretinogram (ERG) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.4.1.5. Fundus Camera
    - 5.4.1.5.1. Fundus Camera Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.4.1.6. Ophthalmoscopes
    - 5.4.1.6.1. Ophthalmoscopes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.4.1.7. Pachymeter
    - 5.4.1.7.1. Pachymeter Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.4.1.8. Other Diagnostic Devices
    - 5.4.1.8.1. Other Diagnostic Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Treatment Devices
- 5.5.1. Treatment Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.5.1.1. Lenses
    - 5.5.1.1.1. Lenses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.5.1.1.2. Bandage Lenses
      - 5.5.1.1.2.1. Bandage Lenses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.5.1.1.3. Intraocular Lenses
      - 5.5.1.1.3.1. Intraocular Lenses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.5.1.2. Laser Devices
    - 5.5.1.2.1. Laser Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.5.1.3. Other Treatment Devices
    - 5.5.1.3.1. Other Treatment Devices Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Medications
- 5.6.1. Medications Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6.2. Antibiotics
  - 5.6.2.1. Antibiotics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6.3. NSAIDs
  - 5.6.3.1. NSAIDs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6.4. Corticosteroids
  - 5.6.4.1. Corticosteroids Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6.5. Lubricants / Artificial Tears
  - 5.6.5.1. Lubricants / Artificial Tears Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6.6. Analgesics / Pain Relievers
  - 5.6.6.1. Analgesics / Pain Relievers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6.7. Other Medications
  - 5.6.7.1. Other Medications Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Veterinary Eye Care Market: By Indication Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. U.S. Veterinary Eye Care Market: By Indication Movement Analysis
6.3. U.S. Veterinary Eye Care Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
- 6.3.1. Eyelid Abnormalities
  - 6.3.1.1. Eyelid Abnormalities Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.2. Cataract
  - 6.3.2.1. Cataract Care Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Glaucoma
  - 6.3.3.1. Glaucoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 6.3.3.2. Retinal Complications
  - 6.3.3.3. Retinal Complications Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4. Uveitis
  - 6.3.4.1. Uveitis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.5. Conjunctivitis
  - 6.3.5.1. Conjunctivitis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.6. Corneal Complications
  - 6.3.6.1. Corneal Complications Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.7. Other Indications
  - 6.3.7.1. Other Indications Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Veterinary Eye Care Market: By Distribution Channel Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. U.S. Veterinary Eye Care Market: By Distribution Channel Movement Analysis
7.3. U.S. Veterinary Eye Care Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 7.3.1. Veterinary Hospitals & Clinics
  - 7.3.1.1. Veterinary Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. Specialty Stores
  - 7.3.2.1. Specialty Stores Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. E-Commerce
  - 7.3.3.1. E-Commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Other Distribution Channels
  - 7.3.4.1. Other Distribution Channels Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Market Participant Categorization
8.2. Company Market Position Analysis/ Heat Map Analysis
8.3. Company Profiles
- 8.3.1. Merck & Co., Inc.
  - 8.3.1.1. Participant's Overview
  - 8.3.1.2. Financial Performance
  - 8.3.1.3. Product Benchmarking
  - 8.3.1.4. Strategic Initiatives
- 8.3.2. An-Vision GmbH
  - 8.3.2.1. Participant's Overview
  - 8.3.2.2. Financial Performance
  - 8.3.2.3. Product Benchmarking
  - 8.3.2.4. Strategic Initiatives
- 8.3.3. Jorgensen Laboratories
  - 8.3.3.1. Participant's Overview
  - 8.3.3.2. Financial Performance
  - 8.3.3.3. Product Benchmarking
  - 8.3.3.4. Strategic Initiatives
- 8.3.4. LKC Technologies Inc.
  - 8.3.4.1. Participant's Overview
  - 8.3.4.2. Financial Performance
  - 8.3.4.3. Product Benchmarking
  - 8.3.4.4. Strategic Initiatives
- 8.3.5. Accutome Inc.
  - 8.3.5.1. Participant's Overview
  - 8.3.5.2. Financial Performance
  - 8.3.5.3. Product Benchmarking
  - 8.3.5.4. Strategic Initiatives
- 8.3.6. Dechra
  - 8.3.6.1. Participant's Overview
  - 8.3.6.2. Financial Performance
  - 8.3.6.3. Product Benchmarking
  - 8.3.6.4. Strategic Initiatives
- 8.3.7. Bausch & Lomb Incorporated
  - 8.3.7.1. Participant's Overview
  - 8.3.7.2. Financial Performance
  - 8.3.7.3. Product Benchmarking
  - 8.3.7.4. Strategic Initiatives
- 8.3.8. Zoetis Services LLC.
  - 8.3.8.1. Participant's Overview
  - 8.3.8.2. Financial Performance
  - 8.3.8.3. Product Benchmarking
  - 8.3.8.4. Strategic Initiatives
- 8.3.9. Ceva Sante Animale
  - 8.3.9.1. Participant's Overview
  - 8.3.9.2. Financial Performance
  - 8.3.9.3. Product Benchmarking
  - 8.3.9.4. Strategic Initiatives
- 8.3.10. Sandoz
  - 8.3.10.1. Participant's Overview
  - 8.3.10.2. Financial Performance
  - 8.3.10.3. Product Benchmarking
  - 8.3.10.4. Strategic Initiatives
- 8.3.11. Boehringer Ingelheim
  - 8.3.11.1. Participant's Overview
  - 8.3.11.2. Financial Performance
  - 8.3.11.3. Product Benchmarking
  - 8.3.11.4. Strategic Initiatives
- 8.3.12. I-Med Animal Health
  - 8.3.12.1. Participant's Overview
  - 8.3.12.2. Financial Performance
  - 8.3.12.3. Product Benchmarking
  - 8.3.12.4. Strategic Initiatives
- 8.3.13. Iridex Corporation
  - 8.3.13.1. Participant's Overview
  - 8.3.13.2. Financial Performance
  - 8.3.13.3. Product Benchmarking
  - 8.3.13.4. Strategic Initiatives
- 8.3.14. Baxter (Welch Allyn)
  - 8.3.14.1. Participant's Overview
  - 8.3.14.2. Financial Performance
  - 8.3.14.3. Product Benchmarking
  - 8.3.14.4. Strategic Initiatives
- 8.3.15. OptoMed
  - 8.3.15.1. Participant's Overview
  - 8.3.15.2. Financial Performance
  - 8.3.15.3. Product Benchmarking
  - 8.3.15.4. Strategic Initiatives
- 8.3.16. Reichert, Inc.
  - 8.3.16.1. Participant's Overview
  - 8.3.16.2. Financial Performance
  - 8.3.16.3. Product Benchmarking
  - 8.3.16.4. Strategic Initiatives
- 8.3.17. Occuity
  - 8.3.17.1. Participant's Overview
  - 8.3.17.2. Financial Performance
  - 8.3.17.3. Product Benchmarking
  - 8.3.17.4. Strategic Initiatives
- 8.3.18. Strategy Mapping
- 8.3.19. Mergers & Acquisitions
- 8.3.20. Partnerships & Collaborations
- 8.3.21. Product launch
- 8.3.22. Others
8.4. List of other key players